American Hospital orders four WasteLog® systems

Pharmacolog has received an order for four WasteLog® systems from UT Southwestern in Dallas, Texas. The systems will be used to control the return of narcotics at four of UT Southwestern’s hospitals in Dallas.

UT Southwestern is one of Texas’ premier academic medical centers and is part of South Western Health Resources, a hospital network with a total of 29 hospitals and over 650 health centers. UT Southwestern has a very extensive research activity that since 1985 has generated 6 Nobel Prizes. After an extensive evaluation of various systems for the examination of returned narcotic drugs, the choice fell on Pharmacolog and WasteLog®. The hospital is acquiring four WasteLog systems to check that returns of narcotic drugs from recent operations have not been manipulated or diluted. The use of WasteLog® is part of UT Southwestern’s Drug Diversion Prevention program. The order is expected to generate revenue of the equivalent of SEK 1 million.

CEO, Mats Högberg comments: “We are extremely proud that UT Southwestern chooses to implement WasteLog® in its program to prevent Drug Diversion. This sends a powerful message to the market and opens new fantastic business opportunities in the US. It has been a long process, much due to the pandemic. To succeed taking this prestigious order, despite the very special circumstances that prevailed during spring and summer, is extraordinarily gratifying. We have worked long-term and purposefully in our commitment to the United States and the team has done an exceptionally good job of finalizing this deal.”

Director of Sales North American Market, Jeffrey Marton comments: “Since onboard with Pharmacolog I have worked extremely hard and maintained continuous efforts to capture business in the United States. Winning this business from UT Southwestern in the middle of the pandemic and beating out our competition is something to be very proud of. I would like to thank the Pharmacolog team and their efforts in helping me win this business as we continue to grow here in the North American Market.”

For more information contact:

Mats Högberg, CEO

Email: mats.hogberg@pharmacolog.com
Phone: +46 70-546 50 21


This information is insider information that Pharmacolog AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on December 8, at 8:35.

About Pharmacolog AB

Pharmacolog is specialized in developing systems and solutions for more effective and safer use of intravenous drugs. The company’s first product, DrugLog®, enables a nurse or pharmacist to quickly and easily verify that an injectable drug has the right identity and concentration. Pharmacolog’s long-term vision is an individually optimized medication for each individual patient, considering all available parameters in the control and distribution of the drug. Further information regarding the company is available at http://www.pharmacolog.com. The company’s Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through CA@mangold.se.

Release